Lienhardt C, Kamate B, Jamet P, Tounkara A, Faye O C, Sow S O, Bobin P
Institut Marchoux, Bamako, Mali.
Int J Lepr Other Mycobact Dis. 1996 Dec;64(4):383-91.
From February 1992 until June 1994, all patients with histologically proven leprosy examined at the Leprology Unit of the Institut Marchoux in Bamako, Mali, were screened for HIV serology. In total, 740 leprosy patients have been tested; 553 known, previously treated leprosy cases and 187 new cases, mainly self-reporting and referred cases. The global seroprevalence in the sample was 1.5% (11/740), and increased from 1.3% in 1992 to 3.1% in 1994. HIV seroprevalence was higher in paucibacillary (PB) than in multibacillary (MB) cases (3.8% versus 0.8%, p < 0.05), and was slightly higher in new cases than in known, already treated cases (2.1% versus 1.3%), although not significantly. Among the 553 known, already treated leprosy patients, 1 out of 7 HIV-seropositive patients relapsed, as opposed to 34 out of 546 HIV-seronegative cases (14.2% versus 6.2%, p = 0.36). Among the new cases, none of the 37 patients with reaction and/or neuritis was HIV positive. In known, treated leprosy cases, there was no difference in the frequency of reactions and/or neuritis between HIV-positive and HIV-negative cases. Migration in a neighboring country appeared to be a risk factor for HIV seropositivity in our sample (chi 2 = 4.5, p = 0.04). In order to estimate the association of HIV with leprosy as compared to the general population, a control group of blood donors was set up, matched for age and sex. There was, however, no difference in HIV seroprevalence between the control group (9/735, 1.2%) and the leprosy group (1.5%). Although leprosy patients recruited for this study constitute a highly selected sample, it appears that HIV infection has little effect on leprosy, particularly on the PB/MB ratio, leprosy reactions and neuritis, but there is a suggestion the HIV infection might be associated with increased frequency of relapse.
1992年2月至1994年6月,在马里巴马科马尔舒研究所麻风病科接受组织学确诊麻风病检查的所有患者均接受了HIV血清学筛查。总共对740例麻风病患者进行了检测,其中553例为已知的既往治疗过的麻风病病例,187例为新病例,主要是自我报告和转诊病例。样本中的总体血清阳性率为1.5%(11/740),并从1992年的1.3%上升至1994年的3.1%。少菌型(PB)病例的HIV血清阳性率高于多菌型(MB)病例(3.8%对0.8%,p<0.05),新病例的血清阳性率略高于已知的已治疗病例(2.1%对1.3%),但差异不显著。在553例已知的已治疗麻风病患者中,7例HIV血清阳性患者中有1例复发,而546例HIV血清阴性病例中有34例复发(14.2%对6.2%,p = 0.36)。在新病例中,37例有反应和/或神经炎的患者均未感染HIV。在已知的已治疗麻风病病例中,HIV阳性和阴性病例在反应和/或神经炎的发生率上没有差异。在我们的样本中,在邻国的迁移似乎是HIV血清阳性的一个危险因素(卡方=4.5,p = 0.04)。为了评估与普通人群相比,HIV与麻风病的关联,设立了一个年龄和性别匹配的献血者对照组。然而,对照组(9/735,1.2%)和麻风病组(1.5%)的HIV血清阳性率没有差异。尽管为本研究招募的麻风病患者构成了一个经过高度挑选的样本,但似乎HIV感染对麻风病影响很小,特别是对PB/MB比例、麻风病反应和神经炎,但有迹象表明HIV感染可能与复发频率增加有关。